 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...1920212223242526272829...3334» |
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_59;
Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS. However overall survival outcomes achieved with TAS102 in real world patients were comparable to findings from this pivotal trial with an acceptable rate of major adverse events.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling. () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_28;
Using a large and uniquely detailed clinical-genomic dataset, we produced results that replicate the observed distribution of ctDNA identified mutations present in aCRC. This genomic information combined with real-world clinical data provides valuable insights into the variety of longitudinal treatments, including before and after comprehensive ctDNA genomic profiling, allowing for detailed outcomes research, especially focused on precision oncology.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
New P2 trial, Head-to-Head, Metastases: Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 8, 2020
P2, N=116, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- ||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Metastases: PRECONNECT: A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). (clinicaltrials.gov) - Dec 8, 2020
P3, N=907, Completed, Sponsor: Institut de Recherches Internationales Servier
This genomic information combined with real-world clinical data provides valuable insights into the variety of longitudinal treatments, including before and after comprehensive ctDNA genomic profiling, allowing for detailed outcomes research, especially focused on precision oncology. Active, not recruiting --> Completed
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
S1 , UFT , TAS 102 ... (Twitter) - Dec 5, 2020
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Combination therapy: .@agrothey, of @west_cancer, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/oQQIsFj5oH (Twitter) - Nov 25, 2020
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Journal, HEOR: Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. (Pubmed Central) - Nov 19, 2020
P3
Active, not recruiting --> Completed Trifluridine/tipiracil (TAS102) is not a cost-effective choice for patients with heavily pretreated metastatic gastric cancer from an American payer perspective.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Retrospective data, Journal: Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. (Pubmed Central) - Nov 19, 2020
However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report. (Pubmed Central) - Nov 19, 2020
Few reports have been published on the use of both palliative re-irradiation to stop bleeding from rectal cancer and palliative low-dose WLRT. Based on our experience with this case, we believe that palliative radiotherapy can be useful in treating patients with a poor prognosis.
- || Clinical, Journal: Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? (Pubmed Central) - Nov 19, 2020
Indirect comparison suggested that the three agents had similar OS but that fruquintinib was superior in terms of PFS compared with that of TAS-102. These three agents had different toxicity profiles.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical, Journal, Combination therapy: Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. (Pubmed Central) - Nov 18, 2020
Trifluridine/tipiracil plus other appropriate local therapy may significantly prolong patients survival with a satisfactory quality of life for patients with refractory mCRC. The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions.
- || Stivarga (regorafenib) / Bayer
Review, Journal: Practical considerations in the use of regorafenib in metastatic colorectal cancer. (Pubmed Central) - Nov 18, 2020
We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.
- ||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: RAMTAS: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Nov 17, 2020
P3, N=426, Recruiting, Sponsor: Institut f
We also highlight key physician-patient communication points to facilitate shared decision-making. Phase classification: P2b --> P3 | N=144 --> 426 | Trial completion date: Jun 2021 --> Jun 2024 | Trial primary completion date: Jan 2021 --> Dec 2023
- ||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Combination therapy: .@agrothey, of @west_cancer, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer #crcsm https://t.co/oQQIsFj5oH (Twitter) - Nov 16, 2020
- | Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Metastases: A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Nov 12, 2020
P2, N=33, Recruiting, Sponsor: National University Hospital, Singapore
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron, dalmitamig (REGN7075) / Regeneron
New P1/2 trial: COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (clinicaltrials.gov) - Nov 11, 2020
P1/2, N=312, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Trial completion date, Metastases: TASCO1: A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (clinicaltrials.gov) - Nov 10, 2020
P2, N=154, Completed, Sponsor: Institut de Recherches Internationales Servier
Phase classification: P2b --> P3 | N=144 --> 426 | Trial completion date: Jun 2021 --> Jun 2024 | Trial primary completion date: Jan 2021 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Sep 2020
- || Stivarga (regorafenib) / Bayer
Clinical, Retrospective data, Journal: A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. (Pubmed Central) - Nov 6, 2020
This was the first study evaluating the associations between polymorphisms in cachexia-associated genes and outcomes in refractory mCRC patients treated with regorafenib. Further studies should be conducted to confirm these associations.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil. (Pubmed Central) - Nov 3, 2020
Further studies should be conducted to confirm these associations. No abstract available
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Giuseppe et al. (Pubmed Central) - Nov 3, 2020
No abstract available No abstract available
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. (Pubmed Central) - Nov 3, 2020
No abstract available No abstract available
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Enrollment open, Metastases: SOREGATT: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 2, 2020
P2, N=340, Recruiting, Sponsor: UNICANCER
No abstract available Not yet recruiting --> Recruiting
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
.@noza512, of @JohnsHopkins, discusses selecting between regorafenib and TAS-102 in colorectal cancer #crcsm https://t.co/MOTAusUw5g (Twitter) - Nov 1, 2020
- || fluorouracil topical / Generic mfg.
Clinical, Review, Journal: Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity. (Pubmed Central) - Nov 1, 2020
The author describes here treatment options for patients with metastatic colorectal cancer who have encountered fluoropyrimidine-induced cardiotoxicity, including switching to a different fluoropyrimidine, switching to a different schedule of intravenous 5-FU, or switching to a non-fluoropyrimidine-containing chemotherapy regimen if one exists. Switching to a non-fluoropyrimidine-containing chemotherapy regimen is usually the most feasible choice for patients with metastatic disease as data on adjuvant setting is usually a fluoropyrimidine or its combination with oxaliplatin at present.
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Important implementations for 1st wave of COVID. I'm really wondering re next wave. And best use of weeks/months between now & then -opportunities for surgery -screenings sooner than later -option for Regorefanib I/o TAS-102 -at home palliative care -more psychological support (Twitter) - Oct 27, 2020
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, P1 data, Journal: A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. (Pubmed Central) - Oct 27, 2020
There was no evidence of allergic reaction to oxaliplatin or severe peripheral sensory neuropathy. Conclusions A combination of FTD/TPI 35 mg/m bid on days 1-5 and 15-19 and oxaliplatin 85 mg/m on days 1 and 15 every 4 weeks could be a suitable regimen for the recommended dose of FTD/TPI plus oxaliplatin in patients with refractory mCRC.
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Clinical, Adverse events: has harder side effects vs no intervention that "gives" pts 7 mths. I'm ok with that. What bothers me is: new, expensive drug w/ horrible SE that gives pts 7.3 mths vs no intervention (and no drug-related toxicities) that "gives" pts 7 mths. Real life example: Lonsurf for CRC. (Twitter) - Oct 25, 2020
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Biomarker, Journal: Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. (Pubmed Central) - Oct 25, 2020
Furthermore, we demonstrated a correlation between the TK1 expression level and cytotoxicity of FTD using cells with inducible TK1 expression, which were generated from TK1-knock-out cells. Based on our finding that the TK1 expression level correlates with sensitivity to FTD, we suggest that FTD/TPI might efficiently treat cancers with high TK1 expression.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Journal: Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. (Pubmed Central) - Oct 23, 2020
This study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Metastases: TAS-102 in Treating Advanced Biliary Tract Cancers (clinicaltrials.gov) - Oct 20, 2020
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC. Trial completion date: Sep 2020 --> Sep 2021
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Metastases: RE-ExPEL: Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (clinicaltrials.gov) - Oct 19, 2020
P=N/A, N=20, Recruiting, Sponsor: Institut f
Trial completion date: Sep 2020 --> Sep 2021 Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date: Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases (clinicaltrials.gov) - Oct 12, 2020
P1, N=24, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Aug 2024 | Trial primary completion date: Dec 2020 --> Aug 2024
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1171;
The ALTAIR trial evaluates the superiority of FTD/TPI over placebo in GALAXY participants with ctDNA status that remains positive after the standard therapy...Funding: This study is funded by Japan Agency for Medical Research and Development (AMED).Grant number: JP19ck0106447. Clinical trial identification: UMIN000039205 on 01/20/2020.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1165;
P3
Funding: Institut de Recherches Internationales Servier. Clinical trial identification: NCT03306394.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1147;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATEJapan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_806;
Moreover, additional tumor tissue and blood samples will also be banked for multi-omics analysis. This study is funded by Japan Agency for Medical Research and Development (AMED).Grant number: JP19ck0106447.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, openlabel, earlyaccess PRECONNECT study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_800;
P3
Results from the Australian cohort are consistent with the global PRECONNECT population and randomised datasets in previously treated mCRC patients. Institut de Recherches Internationales Servier.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_782;
EGFR blockade have a potential to emerge RAS mutated clone. Thus, RAS status should be reconfirmed at the last minute before starting late line chemotherapy using liquid biopsy.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATEJapan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_432;
Moreover, additional tumor tissue and blood samples will also be banked for multi-omics analysis. This study is funded by Japan Agency for Medical Research and Development (AMED).Grant number: JP19ck0106447.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, openlabel, earlyaccess PRECONNECT study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_426;
P3
Results from the Australian cohort are consistent with the global PRECONNECT population and randomised datasets in previously treated mCRC patients. Institut de Recherches Internationales Servier.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_408;
EGFR blockade have a potential to emerge RAS mutated clone. Thus, RAS status should be reconfirmed at the last minute before starting late line chemotherapy using liquid biopsy.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Journal: Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. (Pubmed Central) - Oct 7, 2020
In particular, this association seems to be highly effective in wild-type colon cancer cells, both in sequential and simultaneous schedules. Together, these data may build a rational basis for the future use of TAS-102 combined with 5-FU in adjuvant settings, or as a first-line treatment for metastatic disease.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Clinical, Journal: First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. (Pubmed Central) - Oct 7, 2020
P3
The primary objective is to demonstrate superior progression-free survival with TT-B over capecitabine + bevacizumab. The first patient was enrolled in March 2019.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical, Clinical data, Journal: Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. (Pubmed Central) - Oct 5, 2020
In conclusion, apart from poor ECOG performance status, regorafenib therapy was associated with an increased hospitalization probability during palliative systemic third- and fourth-line therapy in mCRC. However, hospitalizations during regorafenib or TAS-102 therapy did not impact OS beyond second-line therapy.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Meta ... () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1557;
At the defined willingness-to-pay threshold of €54,000 per QALY gained, probabilistic sensitivity analysis showed that FTD/TPI was estimated to have a 64% probability of being cost-effective compared with BSC. CONCLUSIONS : The results indicated that FTD/TPI was estimated to be a cost-effective treatment option for eligible third-line mGC patients, including GEJ, who have received at least two prior therapies for metastatic disease in Greece.
- [VIRTUAL] SIR-Spheres Y-90 Resin Microspheres Versus Best Supportive Care in the Treatment of Unresectable Metastatic Colorectal Cancer Refractory to Chemotherapy- A Cost-Utility Analysis in the UK () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1421;
PSA reported a 96% likelihood of SIR-Spheres Y-90 resin microspheres being cost-effective versus BSC at a willingness-to-pay threshold of £50,000 per QALY gained. CONCLUSIONS SIR-Spheres Y-90 resin microspheres are a cost-effective treatment option compared to BSC for patients with liver-dominant colorectal metastases from the perspective of a UK national healthcare payer.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Opdivo (nivolumab) / Ono Pharma, BMS, irinotecan / Generic mfg.
[VIRTUAL] Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for ... () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_879;
The annual incremental cost associated with the introduction of FΤD/ΤPI was €11,728, €35,184, €46,912, €58,639, and €58,639 for years 1 to 5 respectively, resulting in a total 5-year budget impact of €211,102. CONCLUSIONS : In addition to the clinical benefits, the introduction of FTD/TPI as a third-line treatment option for patients with mGC was predicted to be associated with a limited budget increase for the payer.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal, Real-World Evidence: Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada. (Pubmed Central) - Oct 2, 2020
In advanced mcrc, ftd/tpi is a well-tolerated therapy. The large number of patients enrolled in the access programs within a short period of time is reflective of major clinical need in this area, with many patients being eligible and interested in pursuing treatment in the refractory setting.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. (Pubmed Central) - Oct 2, 2020
The large number of patients enrolled in the access programs within a short period of time is reflective of major clinical need in this area, with many patients being eligible and interested in pursuing treatment in the refractory setting. The results highlight the number of treatment pathways used to treat mCRC in routine UK clinical practice prior to the marketing authorisation and National Institute for Health and Care Excellence approval of trifluridine/tipiracil and highlight the lack of clinical guidelines for mCRC.